Home About us Contact
|
Home About us Contact | ||
|
|
||
Sulfamic Acid (sulfamic + acid)
Selected AbstractsChemInform Abstract: Sulfamic Acid as a Green and Reusable Catalyst for the Preparation of ,-EnaminonesCHEMINFORM, Issue 47 2009Lei Wang Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a "Full Text" option. The original article is trackable via the "References" option. [source] ChemInform Abstract: One-Pot Three-Component Solvent-Free Synthesis of Benzo[4,5]imidazo[1,2-a]pyrimidine Derivatives Catalyzed by Sulfamic Acid.CHEMINFORM, Issue 11 2009Chang-Sheng Yao Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a "Full Text" option. The original article is trackable via the "References" option. [source] ChemInform Abstract: Sulfamic Acid: An Efficient, Cost-Effective, and Reusable Solid Acid Catalyst for the Synthesis of 1,8-Naphthyridines under Solvent-Free Heating and Microwave Irradiation.CHEMINFORM, Issue 6 2009Y. Thirupathi Reddy Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a "Full Text" option. The original article is trackable via the "References" option. [source] ChemInform Abstract: A Convenient and Efficient Protocol for the Synthesis of Symmetrical N,N,-Alkylidine Bisamides by Sulfamic Acid under Solvent-Free Conditions.CHEMINFORM, Issue 25 2008Nagarajan Panneer Selvam Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a "Full Text" option. The original article is trackable via the "References" option. [source] Sulfamic Acid: An Efficient and Green Catalyst for Synthesis of 1,5-Benzodiazepines under Solvent-Free Conditions.CHEMINFORM, Issue 38 2007Min Xia Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF. [source] A Convenient Preparation of Aliphatic and Aromatic N-Sulfonylimines Mediated by Sulfamic Acid in Aqueous Media.CHEMINFORM, Issue 39 2006Zhenjiang Li Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF. [source] Sulfamic Acid as a Cost-Effective and Recyclable Catalyst for Protection of Carbonyls to Acetals and Ketals under Mild Conditions.CHEMINFORM, Issue 18 2005Weizhong Gong No abstract is available for this article. [source] Sulfamic Acid as a Cost-Effective Catalyst Instead of Metal-Containing Acids for Acetolysis of Cyclic Ethers.CHEMINFORM, Issue 48 2004Bo Wang Abstract For Abstract see ChemInform Abstract in Full Text. [source] Inter- and Intramolecular Imino Diels,Alder Reactions Catalyzed by Sulfamic Acid: A Mild and Efficient Catalyst for a One-Pot Synthesis of Tetrahydroquinolines.CHEMINFORM, Issue 19 2004Rajagopal Nagarajan No abstract is available for this article. [source] Ionic Liquid Regulated Sulfamic Acid: Chemoselective Catalyst for the Transesterification of ,-Ketoesters.CHEMINFORM, Issue 40 2003Wang Bo No abstract is available for this article. [source] Sulfamic Acid as a Green and Reusable Catalyst for the Preparation of , -EnaminonesCHINESE JOURNAL OF CHEMISTRY, Issue 7 2009Lei WANG Abstract Sulfamic acid can effectively catalyze the reaction of ( -diketones with arylamines to afford the , -enaminones. The present method offers several advantages, such as high yield, short reaction time, mild conditions, easy work-up and catalyst recyclability. [source] Sulfamic acid: An efficient and green catalyst for synthesis of 1,5-benzodiazepines under solvent-free conditionsHETEROATOM CHEMISTRY, Issue 4 2007Min Xia It is described that sulfamic acid can be utilized as an effective and green catalyst for the synthesis of 1,5-benzodiazepines in high yields from the solvent-free condensation of o-phenylenediamine (1) and ketones (2). © 2007 Wiley Periodicals, Inc. Heteroatom Chem 18:354,358, 2007; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.20305 [source] Sulfamic acid catalyzed one-pot synthesis of 2,5-diaryl-1,3,4-oxadiazoles under microwave irradiation and conventional heatingJOURNAL OF HETEROCYCLIC CHEMISTRY, Issue 2 2009J. Venu Madhav Sulfamic acid has been found to be an efficient catalyst for the one-pot synthesis of novel 2,5-diaryl-1,3,4-oxadiazoles by condensation of different coumarinoyl hydrazides with various coumarinoyl or quinolinoyl chlorides under microwave irradiation and conventional heating. Some of the advantages of this method are low reaction times, operational simplicity, and high yields. J. Heterocyclic Chem., (2009) [source] Sulfamic Acid as a Green and Reusable Catalyst for the Preparation of , -EnaminonesCHINESE JOURNAL OF CHEMISTRY, Issue 7 2009Lei WANG Abstract Sulfamic acid can effectively catalyze the reaction of ( -diketones with arylamines to afford the , -enaminones. The present method offers several advantages, such as high yield, short reaction time, mild conditions, easy work-up and catalyst recyclability. [source] Sulfamic acid: An efficient and green catalyst for synthesis of 1,5-benzodiazepines under solvent-free conditionsHETEROATOM CHEMISTRY, Issue 4 2007Min Xia It is described that sulfamic acid can be utilized as an effective and green catalyst for the synthesis of 1,5-benzodiazepines in high yields from the solvent-free condensation of o-phenylenediamine (1) and ketones (2). © 2007 Wiley Periodicals, Inc. Heteroatom Chem 18:354,358, 2007; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.20305 [source] Sulfamic acid-catalyzed synthesis of 13-aryl-indeno[1,2- b]-naphtha[1,2-e]pyran-12(13H)-ones under solvent-free conditionsJOURNAL OF HETEROCYCLIC CHEMISTRY, Issue 5 2010Li Qiang Wu The reaction of ,-naphthol with arylaldehydes and 2H-indene-1,3-dione in the presence of sulfamic acid (3 mol %) under solvent-free conditions led to 13-aryl-indeno[1,2- b]naphtho[1,2- e]pyran-12(13H)-ones in good yields. J. Heterocyclic Chem., (2010). [source] Sulfamates and their therapeutic potentialMEDICINAL RESEARCH REVIEWS, Issue 2 2005Jean-Yves Winum Abstract Starting from the very simple molecule sulfamic acid, O -substituted-, N -substituted-, or di-/tri-substituted sulfamates may be obtained, which show specific biological activities which were or started to be exploited for the design of many types of therapeutic agents. Among them, sulfamate inhibitors of aminoacyl-tRNA synthetases (aaRSs) were recently reported, constituting completely new classes of antibiotics, useful in the fight of drug-resistant infections. Anti-viral agents incorporating sulfamate moieties have also been obtained, with at least two types of such derivatives investigated: the nucleoside/nucleotide human immunodeficiency virus (HIV) reverse transcriptase inhibitors, and the HIV protease inhibitors (PIs). In the increasing armamentarium of anti-cancer drugs, the sulfamates occupy a special position, with at least two important targets evidenced so far: the steroid sulfatases (STSs) and the carbonic anhydrases (CAs). An impressing number of inhibitors of STSs of the sulfamate type have been reported in the last years, with several compounds, such as 667COUMATE among others, progressing to clinical trials for the treatment of hormone-dependent tumors (breast and prostate cancers). This field is rapidly evolving, with many types of new inhibitors being constantly reported and designed in such a way as to increase their anti-tumor properties, and decrease undesired features (for example, estrogenicity, a problem encountered with the first generation such inhibitors, such as EMATE). Among the many isozymes of CAs, at least two, CA IX and CA XII, are highly overexpressed in tumors, being generally absent in the normal tissues. Inhibition of tumor-associated CAs was hypothesized to lead to novel therapeutic approaches for the treatment of cancer. Many sulfamates act as very potent (low nanomolar) CA inhibitors. The X-ray crystal structure of the best-studied isozyme, CA II, with three sulfamates (sulfamic acid, topiramate, and EMATE) has recently been reported, which allowed for a rationale drug design of new inhibitors. Indeed, low nanomolar CA IX inhibitors of the sulfamate type have been reported, although such compounds also act as efficient inhibitors of isozymes CA I and II, which are not associated with tumors. A large number of anti-convulsant sulfamates have been described, with one such compound, topiramate, being widely used clinically as anti-epileptic drug. By taking into consideration a side effect of topiramate, an anti-epileptic drug leading to weight loss in some patients, it has recently been proposed to use this drug and related sulfamates for the treatment of obesity. The rationale of this use is based on the inhibition of the mitochondrial CA isozyme, CA V, involved in lipogenesis. Some sulfamates were also shown to possess potent inhibitory activity against acyl coenzyme A:cholesterol acyltransferase, an enzyme involved in cholesterol metabolism. One such agent, avasimibe, is in advanced clinical trials for the treatment of hyperlipidemia and atherosclerosis. Thus, the sulfamate moiety offers very attractive possibilities for the drug design of various pharmacological agents, which are on one hand due to the relative ease with which such compounds are synthesized, and on the other one, due to the fact that biological activity of most of them is impressive. © 2004 Wiley Periodicals, Inc. [source] | ||||||||||